Pharma

Your Article Summary

See Latest Articles

Landmark Trial ONTARGET(R) Proves Telmisartan is as Protective as Ramipril and Better Tolerated in a Broad High-Risk Cardiovascular Population. From ONTARGET(R) it May be Concluded That Telmisartan can Prevent Every 5th Serious Cardiovascular Event
Corporate News Releases - The Healthcare Sales & Marketing Network, 04/04/08

The results of the landmark ONTARGET® Trial have proven that telmisartan, brand name MICARDIS®, a modern angiotensin II receptor blocker (ARB), is as protective as the current gold standard, ramipril, in reducing the risk of cardiovascular death, myocardial infarction, stroke, and hospitalisation for congestive heart failure in a broad cross-section of high-risk cardiovascular patients and with better tolerability.

Today in Physician/Patient Trends...keeping you current

Receive free subspecialty "5-minute updates" via email

Major Study Finds Anti-HIV Gel Ineffective Among Women
National Institute of Allergy and Infectious Disease - News, 12/17/09

Trends in hypertension treatment in diabetes
Current Hypertension Reports, 12/09/09

New program helps educate survivors of a heart event about the importance of maintaining good physical and emotional health
Daiichi Sankyo, 12/08/09

 See all of Physician/Patient Trends